Premium
Mutations spectrum of GNE in hereditary inclusion body myopathy sparing the quadriceps
Author(s) -
Eisenberg Iris,
GrabovNardini Gil,
Hochner Hagit,
Korner Mira,
Sadeh Menachem,
Bertorini Tulio,
Bushby Kate,
Castellan Claudio,
Felice Kevin,
Mendell Jerry,
Merlini Luciano,
Shilling Christopher,
Wirguin Itshak,
Argov Zohar,
MitraniRosenbaum Stella
Publication year - 2003
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.9100
Subject(s) - missense mutation , compound heterozygosity , genetics , nonsense mutation , biology , mutation , myopathy , nonsense , heterozygote advantage , gene , genotype
Hereditary Inclusion Body Myopathy (HIBM) is a unique group of neuromuscular disorders characterized by adult onset and a typical muscle pathology. We have recently identified the gene encoding for a bifunctional enzyme, UDP‐N‐acetylglucosamine 2 epimerase/ N ‐acetylmannosamine kinase (GNE), as the mutated gene in the prototype form of the disease presenting quadriceps sparing, particularly common in Middle Eastern Jews. Interestingly, we have identified the homozygous M712T Middle Eastern Jewish mutation also in two unrelated Middle Eastern Moslem families. We have also evaluated the involvement of GNE in several families from worldwide non‐Jewish ethnic origins presenting symptoms similar to the Middle Eastern HIBM prototype. A total of 14 GNE mutations were identified (one nonsense and 13 missense), of which six are novel: an homozygous missense mutation in a consanguineous family from Italy and in a non consanguineous family from USA, and distinct compound heterozygotes in families from Germany, Italy, Ireland, Bahamas, USA and East India. This study brings to 17 the number of reported GNE mutations in quadriceps sparing myopathy, occurring either in the epimerase or the kinase domain of the enzyme. The mechanism leading to this unique phenotype still remains to be elucidated. © 2002 Wiley‐Liss, Inc.